^
BIOMARKER:

MSLN expression

i
Other names: MSLN, CAK1, MPF, Mesothelin
Entrez ID:
Related biomarkers:
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/08/2021
Initiation :
02/08/2018
Primary completion :
02/02/2022
Completion :
02/02/2022
PD-L1 • MSLN • CCL2
|
MSLN expression
|
Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/30/2021
Initiation :
08/29/2019
Primary completion :
12/01/2021
Completion :
07/01/2023
MSLN
|
MSLN expression
|
Xeljanz (tofacitinib) • LMB-100
Phase 1
Amgen
Recruiting
Last update posted :
09/30/2021
Initiation :
04/29/2021
Primary completion :
10/06/2024
Completion :
10/06/2024
MSLN
|
MSLN expression • MSLN positive
|
zeluvalimab (AMG 404)
Phase 1
Fred Hutchinson Cancer Research Center
Recruiting
Last update posted :
09/24/2021
Initiation :
10/23/2021
Primary completion :
11/10/2022
Completion :
11/10/2037
MSLN • HLA-A
|
MSLN expression
|
fludarabine IV • cyclophosphamide intravenous
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/21/2021
Initiation :
03/28/2019
Primary completion :
04/30/2022
Completion :
04/30/2022
CD8 • MSLN
|
MSLN expression • MSLN positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
09/11/2019
Primary completion :
04/30/2023
Completion :
03/31/2024
EGFR • PD-L1 • KRAS • ALK • ROS1 • MSLN
|
KRAS mutation • EGFR mutation • ALK rearrangement • MSLN expression
|
Keytruda (pembrolizumab) • LMB-100
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
08/13/2021
Initiation :
06/01/2016
Primary completion :
06/01/2022
Completion :
06/01/2022
HER-2 • PD-L1 • MSLN
|
HER-2 negative • MSLN expression
|
cyclophosphamide intravenous • rimiducid (AP1903)
Phase 1
Shanghai 6th People's Hospital
Recruiting
Last update posted :
08/10/2021
Initiation :
08/16/2019
Primary completion :
01/01/2023
Completion :
01/01/2023
MSLN
|
MSLN expression • MSLN positive
|
fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous
Phase 1b
Bayer
Completed
Last update posted :
08/06/2021
Initiation :
05/26/2017
Primary completion :
09/16/2020
Completion :
07/26/2021
MSLN
|
MSLN expression
|
cisplatin • gemcitabine • anetumab ravtansine (BAY 94-9343)
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/20/2021
Initiation :
09/30/2020
Primary completion :
09/01/2023
Completion :
09/01/2023
MSLN
|
MSLN expression
|
ATA2271 • cyclophosphamide intravenous • engineered autologous T cells
Phase 1
Bayer
Completed
Last update posted :
07/09/2021
Initiation :
04/14/2016
Primary completion :
07/31/2018
Completion :
08/19/2019
MSLN
|
MSLN expression
|
anetumab ravtansine (BAY 94-9343)
Phase 1
Bayer
Completed
Last update posted :
07/09/2021
Initiation :
09/07/2011
Primary completion :
12/31/2016
Completion :
07/30/2019
MSLN
|
MSLN expression
|
anetumab ravtansine (BAY 94-9343)
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
07/02/2021
Initiation :
03/01/2017
Primary completion :
03/01/2025
Completion :
03/01/2025
PD-L1
|
MSLN expression
|
fludarabine IV
Phase 1/2
TCR2 Therapeutics
Recruiting
Last update posted :
06/29/2021
Initiation :
04/15/2019
Primary completion :
12/01/2021
Completion :
01/01/2023
MSLN
|
MSLN expression • MSLN positive
|
fludarabine IV • gavocabtagene autoleucel (TC-210)
Phase 1/2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
04/01/2021
Initiation :
05/01/2015
Primary completion :
04/01/2023
Completion :
04/01/2023
PD-L1 • MSLN
|
MSLN expression
|
Keytruda (pembrolizumab) • cyclophosphamide intravenous • genetically engineered anti-mesothelin autologous T cells • paracetamol
Phase 2
Yale University
Completed
Last update posted :
01/22/2021
Initiation :
05/11/2017
Primary completion :
08/06/2019
Completion :
12/11/2019
MSLN
|
MSLN expression
|
anetumab ravtansine (BAY 94-9343)
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
12/17/2020
Initiation :
09/15/2017
Primary completion :
09/01/2021
Completion :
09/01/2021
MSLN • ALB
|
MSLN expression
Phase 2
Bayer
Completed
Last update posted :
11/04/2020
Initiation :
12/03/2015
Primary completion :
05/31/2017
Completion :
09/06/2019
MSLN
|
MSLN expression
|
pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
10/02/2020
Initiation :
03/01/2011
Primary completion :
09/01/2022
Completion :
09/01/2022
MSLN
|
MSLN expression • MSLN positive
Phase 1
Bristol-Myers Squibb
Completed
Last update posted :
03/19/2020
Initiation :
10/14/2016
Primary completion :
09/06/2017
Completion :
09/06/2017
MSLN
|
MSLN expression
|
BMS-986148
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
06/06/2019
Initiation :
05/11/2011
Primary completion :
08/03/2016
Completion :
08/07/2017
ALK • MSLN
|
EGFR mutation • ALK translocation • MSLN expression
|
pentostatin • SS1(dsFv)-PE38 • cyclophosphamide intravenous
Phase 1/2
Second Affiliated Hospital, School of Medicine,...
Recruiting
Last update posted :
04/16/2019
Initiation :
04/20/2019
Primary completion :
04/20/2022
Completion :
04/20/2023
MSLN
|
MSLN expression • MSLN positive
|
fludarabine IV
Phase 1
Zhejiang University
Recruiting
Last update posted :
04/10/2019
Initiation :
04/10/2019
Primary completion :
10/01/2021
Completion :
04/01/2022
MSLN
|
MSLN expression • MSLN positive
|
fludarabine IV • anti- MESO CAR-T cells
Phase 1
Allife Medical Science and Technology Co., Ltd.
Not yet recruiting
Last update posted :
01/31/2019
Initiation :
03/01/2019
Primary completion :
11/01/2020
Completion :
11/01/2021
PD-L1 • PD-1 • MSLN
|
MSLN expression • MSLN positive
|
anti-Mesothelin CAR NK Cells • anti-mesothelin gene engineered lymphocytes
Phase 1/2
Shanghai Cell Therapy Research Institute
Recruiting
Last update posted :
08/03/2018
Initiation :
08/06/2018
Primary completion :
08/03/2020
Completion :
12/03/2020
MSLN
|
MSLN expression
|
fludarabine IV • αPD1-MSLN-CAR T Cells
Phase 1
Bayer
Completed
Last update posted :
06/04/2018
Initiation :
08/14/2015
Primary completion :
04/28/2017
Completion :
07/04/2017
MSLN
|
MSLN expression
|
anetumab ravtansine (BAY 94-9343)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
07/02/2017
Initiation :
12/29/2009
Primary completion :
09/28/2011
Completion :
09/28/2011
MSLN
|
MSLN expression
|
Avastin (bevacizumab) • carboplatin • paclitaxel • SS1(dsFv)-PE38
Phase 1
Morphotek
Completed
Last update posted :
09/30/2016
Initiation :
09/01/2011
Primary completion :
03/01/2013
Completion :
03/01/2013
MSLN
|
MSLN expression
|
amatuximab (MORAb-009)
Phase 1
Shanghai GeneChem Co., Ltd.
Recruiting
Last update posted :
03/11/2016
Initiation :
03/01/2016
Primary completion :
02/01/2018
Completion :
09/01/2018
MSLN
|
MSLN expression
|
meso-CART
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
04/30/2015
Initiation :
12/01/2000
MSLN
|
MSLN expression
|
SS1(dsFv)-PE38
Phase 1
Morphotek
Completed
Last update posted :
07/17/2014
Initiation :
05/01/2006
Primary completion :
09/01/2008
Completion :
09/01/2008
MSLN
|
MSLN expression • MSLN positive
|
amatuximab (MORAb-009)